DeepMed Research

Tucidinostat

Generic Name: Tucidinostat

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉FN_₄O_₂

CAS Number: 1616493-44-7

Unique Ingredient Identifier: 87CIC980Y0

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Clinical Trials

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 40

Registration Number: NCT06547476

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Phase 2

Not yet recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Polatuzumab vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Orelabrutinib
Drug: Venetoclax
Drug: Chidamide
Drug: Penpulimab
Drug: Lenalidomide

First Posted Date: 2024-07-24

Last Posted Date: 2024-07-24

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 528

Registration Number: NCT06516978

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Tucidinostat
Drug: Fruquintinib
Drug: Sintilimab
Drug: Bevacizumab

First Posted Date: 2024-07-12

Last Posted Date: 2024-12-03

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 430

Registration Number: NCT06497985

Locations: 🇨🇳
Rui-Hua Xu, Guangzhou, Guangdong, China

Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: PTCL

Interventions: Drug: Toripalimab
Drug: chidamide

First Posted Date: 2024-07-09

Last Posted Date: 2024-07-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 43

Registration Number: NCT06492629

Locations: 🇨🇳
Department of Medical Oncology, Beijing, Beijing, China

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Phase 2

Not yet recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Anthracyclines or anthraquinones
Drug: Chidamide
Drug: Venetoclax
Drug: cytarabine
Drug: azacitidine

First Posted Date: 2024-06-11

Last Posted Date: 2024-06-11

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 240

Registration Number: NCT06451861

Locations: 🇨🇳
Foshan First People's Hospital, Foshan, Guangdong, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 10 locations

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

Phase 2

Not yet recruiting

Conditions: Liver Cancer

Interventions: Drug: chidamide combined with Sintilimab and bevacizumab

First Posted Date: 2024-05-10

Last Posted Date: 2024-05-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 48

Registration Number: NCT06408623

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Not Applicable

Not yet recruiting

Conditions: Acute Myeloid Leukemia
AML

Interventions: Drug: Chidamide
Drug: Venetoclax
Drug: azacitidine

First Posted Date: 2024-04-26

Last Posted Date: 2024-04-30

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 184

Registration Number: NCT06386302

Locations: 🇨🇳
Blood Hospital, Tianjin, Tianjin, China

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Phase 2

Not yet recruiting

Conditions: Colo-rectal Cancer

Interventions: Drug: Tislelizumab
Drug: Fruquintinib
Drug: Chidamide

First Posted Date: 2024-01-23

Last Posted Date: 2024-01-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 17

Registration Number: NCT06218888

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: chidamide in combination with venetoclax and azacitidine (VAC)

First Posted Date: 2024-01-23

Last Posted Date: 2025-02-04

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 32

Registration Number: NCT06220162

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Phase 2

Recruiting

Conditions: Follicular Lymphoma
Refractory B-Cell Lymphoma
Relapsed Non-Hodgkin Lymphoma

Interventions: Drug: Chidamide combined with Linperlisib

First Posted Date: 2023-12-06

Last Posted Date: 2025-02-19

Lead Sponsor: The First Affiliated Hospital of Xiamen University

Target Recruit Count: 33

Registration Number: NCT06158386

Locations: 🇨🇳
Bing Xu, Xiamen, Fujian, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy